Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325962 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension
A Phase 2 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00325962 is a Phase 2 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 84 participants.
The verdict
NCT00325962, a Phase 2 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether 6R-BH4 (sapropterin dihydrochloride) is safe and effective in the treatment of poorly controlled hypertension in the presence or absence of type 2 diabetes.
Interventions
- DRUG 6R-BH4 (sapropterin dihydrochloride)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00325962
The ClinicalTrials.gov registry entry for NCT00325962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 6R-BH4 (sapropterin dihydrochloride) is the first listed.
NCT00325962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00325962 about?
NCT00325962 is a clinical study titled "A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension". The purpose of this study is to determine whether 6R-BH4 (sapropterin dihydrochloride) is safe and effective in the treatment of poorly controlled hypertension in the presence or absence of type 2 diabetes.
What is the current status of trial NCT00325962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2006-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00325962?
The interventions under investigation include: 6R-BH4 (sapropterin dihydrochloride) (DRUG).
Who is sponsoring clinical trial NCT00325962?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.